Analysis of the difference between Sorafenib/Nexavar and Donafenib

Sorafenib/Nexavar and Donafenib are multi-target tyrosine kinase inhibitors that are widely used in the treatment of solid tumors such as liver cancer. Although they are oral anti-cancer drugs with similar structures, there are some differences in pharmacokinetics, metabolic properties and clinical application details. Sorafenib is the first targeted drug approved by the FDA for the treatment of advanced hepatocellular carcinoma. Its mechanism of action mainly inhibits tumor cell proliferation and tumor angiogenesis by inhibiting Raf kinase and angiogenesis-related pathways such as VEGFR and PDGFR. Donafenib is a structurally optimized product based on sorafenib. It introduces a more stable metabolism modification into the chemical structure, making it easier to maintain a higher concentration of active drugs in the body and reducing the occurrence of certain adverse reactions.

Donafenib modifies the hydroxyl group of sorafenib in the molecular structure, thereby extending the half-life of the drug in plasma. This structural modification not only improves the stability of the drug in liver metabolism, but also reduces the risk of toxicity caused by active metabolites. Clinical studies have shown that its incidence of some adverse reactions, such as rash and hand-foot syndrome, is slightly lower than that of sorafenib. In addition, the study population of donafenib in clinical trials is mainly Asian patients, and its efficacy data is more representative of the Eastern population, so it attracted special attention when it was approved in mainland China.

Although these two drugs have similar indications for the treatment of advanced liver cancer, doctors will make individual judgments based on the patient's tolerance, previous treatment history, and financial affordability when choosing. The emergence of donafenib provides another treatment option for patients who cannot tolerate sorafenib, and also provides more possibilities for targeted therapy of liver cancer.

Reference materials:https://www.nexavar.com/